Targeting farnesoid X receptor for liver and metabolic disorders

Trends in Molecular Medicine

Volumn 13, Issue 7, 2007, Pages 298-309

  Fiorucci, Stefano ^a   Rizzo, Gianni ^a   Donini, Annibale ^a   Distrutti, Eleonora ^a   Santucci, Luca ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6ALPHA ETHYLCHENODEOXYCHOLIC ACID; BILE ACID; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; CHENODEOXYCHOLIC ACID DERIVATIVE; CHOLESTEROL; CHOLIC ACID; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FARNESOID X RECEPTOR MODULATOR; FEXARAMINE; GENE PRODUCT; GUGGULSTERONE; INT 747; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; XENOBIOTIC AGENT;

BILE ACID SYNTHESIS; BIOSENSOR; CHOLESTASIS; CHOLESTEROL METABOLISM; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; GALLSTONE; HUMAN; LIVER DISEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CHOLESTASIS; DNA-BINDING PROTEINS; HUMANS; LIGANDS; LIVER; LIVER DISEASES; METABOLIC DISEASES; MODELS, BIOLOGICAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 34347325158     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.06.001     Document Type: Review

References (95)

1. Forman B.M., et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81 (1995) 687-693
2. Huber R.M., et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290 (2002) 35-43
3. Zhang Y., et al. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 278 (2003) 104-110
4. Otte K., et al. Identification of farnesoid X receptor β as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell. Biol. 23 (2003) 864-872
5. Makishima M., et al. Identification of a nuclear receptor for bile acids. Science 284 (1999) 1362-1365
6. Parks D.J., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284 (1999) 1365-1368
7. Wang H., et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3 (1999) 543-553
8. Maloney P.R., et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 43 (2000) 2971-2974
9. Pellicciari R., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45 (2002) 3569-3572
10. Downes M., et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11 (2003) 1079-1092
11. Sinal C.J., et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102 (2000) 731-744
12. Pellicciari R., et al. Farnesoid X Receptor: from structure to potential clinical applications. J. Med. Chem. 48 (2005) 5383-5403
13. Rizzo G., et al. The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol. Pharmacol. 68 (2005) 551-558
14. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72 (2003) 137-174
15. Zollner G., et al. Role of Nuclear receptors in the adaptive response to bille acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3 (2006) 231-250
16. Goodwin B., et al. Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 223-228
17. Makishima M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296 (2002) 1313-1316
18. Guo G.L., et al. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278 (2003) 45062-45071
19. Edwards P.A., et al. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43 (2002) 2-12
20. Zhang J., et al. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279 (2004) 49517-49522
21. Kawamata Y., et al. A G-protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278 (2003) 9435-9440
22. Watanabe M., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006) 484-489
23. Levy C., et al. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin. Liver Dis. 26 (2006) 22-30
24. Bergasa N.V., et al. Primary biliary cirrhosis: report of a focus study group. Hepatology 40 (2004) 1013-1020
25. Davis R.A., et al. Regulation of cholesterol-7α-hydroxylase: BAREly missing a SHP. J. Lipid Res. 43 (2002) 533-543
26. Chiang J.Y., et al. Regulation of cholesterol 7α-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRα). Gene 262 (2001) 257-265
27. Goodwin B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6 (2000) 517-526
28. Kalaany N.Y., and Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68 (2006) 159-191
29. Lu T.T., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6 (2000) 507-515
30. Brendel C., et al. The small heterodimer partner interacts with the liver X receptor α and represses its transcriptional activity. Mol. Endocrinol. 16 (2002) 2065-2076
31. Kerr T.A., et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev. Cell 2 (2002) 713-720
32. Wang L., et al. Redundant pathways for negative feedback regulation of bile acid production. Dev. Cell 2 (2002) 721-731
33. Denson L.A., et al. The orphan nuclear receptor, Shp, mediates bile acid-induced inhibition of the rat bile acid transporter Ntcp. Gastroenterology 121 (2001) 140-147
34. Kullak-Ublick G.A., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120 (2001) 525-533
35. Ananthanarayanan M., et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276 (2001) 28857-28865
36. Kullak-Ublick G.A., and Becker M.B. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev. 35 (2003) 305-317
37. Kast H.R., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277 (2002) 2908-2915
38. Huang L., et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 278 (2003) 51085-51090
39. Ballatori N., et al. OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42 (2005) 1270-1279
40. Grober J., et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. 274 (1999) 29749-29754
41. Pircher P.C., et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 278 (2003) 27703-27711
42. Song C.S., et al. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 276 (2001) 42549-42556
43. Barbier O., et al. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124 (2003) 1926-1940
44. Gnerre C., et al. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14 (2004) 635-645
45. Jung D., et al. Pregnane x receptor is a target of farnesoid x receptor. J. Biol. Chem. 281 (2006) 19081-19091
46. Lehmann J.M., et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102 (1998) 1016-1023
47. Sonoda J., et al. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13801-13806
48. Paumgartner G., and Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36 (2002) 525-531
49. Marschall H.U., et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129 (2005) 476-485
50. Bell G.D., et al. Serum lipids in cholelithiasis: effect of chenodeoxycholic acid therapy. BMJ 3 (1973) 520-523
51. Miller N.E., and Nestel P.J. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet 2 (1974) 929-931
52. Claudel T., et al. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2020-2030
53. Hirokane H., et al. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279 (2004) 45685-45692
54. Kast H.R., et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15 (2001) 1720-1728
55. Watanabe M., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113 (2004) 1408-1418
56. Lambert G., et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278 (2003) 2563-2570
57. Zhang Y., et al. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 18 (2004) 157-169
58. Rizzo G., et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol. 70 (2006) 1164-1173
59. Cariou B., et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281 (2006) 11039-11049
60. Anisfeld A.M., et al. Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J. Biol. Chem. 278 (2003) 20420-20428
61. Stayrook K.R., et al. Regulation of carbohydrate metabolism by the farnesoid x receptor. Endocrinology 146 (2005) 984-991
62. Yamagata K., et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 279 (2004) 23158-23165
63. Duran-Sandoval D., et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 280 (2005) 29971-29979
64. Duran-Sandoval D., et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53 (2004) 890-898
65. Zhang Y., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1006-1011
66. Ma K., et al. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116 (2006) 1102-1109
67. Liu Y., et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112 (2003) 1678-1687
68. Fiorucci S., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313 (2005) 604-612
69. Stedman C., et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11323-11328
70. Marschall H.U., et al. Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J. Lipid Res. 47 (2006) 582-592
71. Cherrington N.J., et al. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J. Pharmacol. Exp. Ther. 300 (2002) 97-104
72. Assem M., et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279 (2004) 22250-22257
73. Wagner M., et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42 (2005) 420-430
74. Huang W., et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4156-4161
75. Friedman S.L. Liver fibrosis - from bench to bedside. J. Hepatol. 38 Suppl. 1 (2003) S38-S53
76. Fiorucci S., et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 314 (2005) 584-595
77. Fiorucci S., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 (2004) 1497-1512
78. Fiorucci S., et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor γ contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J. Pharmacol. Exp. Ther. 315 (2005) 58-68
79. Wright M.C. The impact of pregnane X receptor activation on liver fibrosis. Biochem. Soc. Trans. 34 (2006) 1119-1123
80. Marra F., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119 (2000) 466-478
81. Farrell G.C. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 Suppl 1 (2006) S99-S112
82. Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis and the metabolic syndrome. Am. J. Med. Sci. 330 (2005) 326-335
83. Neuschwander-Tetri B.A., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
84. Belfort R., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355 (2006) 2297-2307
85. Huang W., et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312 (2006) 233-236
86. Moschetta A., et al. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 10 (2004) 1352-1358
87. Hanniman E.A., et al. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46 (2005) 2595-2604
88. Bilz S., et al. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E716-E722
89. Inagaki T., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3920-3925
90. Inagaki T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2 (2005) 217-225
91. Neimark E., et al. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40 (2004) 149-156
92. Claudel T., et al. The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism. Rev. Endocr. Metab. Disord. 5 (2004) 319-326
93. Urizar N.L., et al. A natural product that lowers cholesterol as an antagonist ligand for the FXR. Science 296 (2002) 1703-1706
94. Burris T.P., et al. The hypolipidemic natural product guggulsterone Is a promiscuous steroid receptor ligand. Mol. Pharmacol. 67 (2005) 948-954
95. Szapary P.O., et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. J. Am. Med. Assoc. 290 (2003) 765-772